Ajaaz Hussain
Radiopharmaceutical Scientist The Royal Marsden NHS
Ajaaz Hussain is a Radiopharmaceutical Scientist at The Royal Marsden NHS Foundation Trust, where he leads the delivery of radiopharmaceutical clinical trials, supporting the translation of innovative targeted therapies into clinical practice. He specialises in implementing complex study protocols through study set-up, radiopharmaceutical handling, pharmacokinetic sampling, quality assurance, and multidisciplinary trial coordination. His background also includes quality assurance in radiopharmacy and experience supporting Gallium-68 and Technetium-99m production. Enthusiastic about improving patient access to novel radiopharmaceuticals, Ajaaz collaborates closely with pharmaceutical sponsors, manufacturers, and clinical teams to overcome operational challenges and accelerate the successful delivery of clinical trials across the UK.
Seminars
Experience a fast-paced debate, where isotope specialists will each present the strongest case for their radionuclide before joining a moderated discussion comparing clinical evidence, manufacturing readiness, supply considerations and commercial potential. Hear contrasting perspectives, challenge conventional thinking and take part in the discussion as the audience helps determine which isotope will define the next five years of TRP development.
- Comparing the scientific, clinical, manufacturing and commercial advantages of emerging isotopes including Actinium-225, Lead-212, Copper-67, Terbium, Astatine-211 and Lutetium-177
- Evaluating which radionuclides are best positioned to win across therapeutic efficacy, supply scalability, dosimetry flexibility, theranostic integration and global clinical applicability
- Challenging each isotope expert to defend why their radionuclide will become the hottest, most commercially impactful and most clinically transformative isotope over the next five years
- Exploring the growing importance of Gallium-68 imaging in radiopharmaceutical clinical development and patient selection strategies
- Navigating the operational, infrastructure and regulatory considerations required to establish and expand Gallium-68 production capabilities
- Discussing how developers, manufacturers and clinical centres can work together to address supply constraints and support future radiopharmaceutical growth
- Sharing real-world lessons from supporting radiopharmaceutical clinical trials across the NHS, from study set-up through to patient treatment and follow-up
- Exploring the operational challenges associated with dosimetry, pharmacokinetic sampling, radiopharmaceutical handling and cross-functional coordination
- Examining how sponsors and clinical sites can work together more effectively to accelerate study activation and execution
- Identifying opportunities to strengthen collaboration between pharma, biotech and NHS centres to improve trial delivery and patient access to innovative therapies
